Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy

CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or "IceCure Medical") (NASDAQ:ICCM), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it intends to effect a one-for-thirty reverse split (the "Reverse Share Split") of the Company's ordinary shares, no par value per share, (the "Ordinary Shares"), as part of its proactive efforts to regain compliance with the Nasdaq $1.00 minimum bid price requirement and support its broader capital markets strategy. The Ordinary Shares continue to trade on the Nasdaq Capital Market under the existing symbol "ICCM" and will begin trading on a split-adjusted basis when the market opens on June 4, 2026. The new CUSIP number for the Ordinary Shares following the Reverse Share Split will be M53071201.

The primary purpose of the Reverse Share Split is to increase the per-share trading price of the Company's Ordinary Shares to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. Under applicable Nasdaq rules, the Company has until November 9, 2026 to cure the non-compliance. By effecting the Reverse Share Split at this time, the Company intends to proactively satisfy these regulatory requirements and maintain the listing of its Ordinary Shares on Nasdaq.